At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VCNX Vaccinex Inc.
Trading 11-22 10:21:34 EST
3.58
+0.03
+0.85%
High3.63
Low3.52
Vol16.89K
Open3.52
D1 Closing3.55
Amplitude3.10%
Mkt Cap9.31M
Tradable Cap4.71M
Total Shares2.60M
T/O60.82K
T/O Rate1.28%
Tradable Shares1.32M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Vaccinex Reports Improved Immunity Correlating With Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Vaccinex to Report Promising New Efficacy Data for Signal-Ad Phase 1B/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (Ctad) Conference on October 31, 2024
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.